Non-interventional Study To Evaluate Efficacy And Safety Of Refacto Af In The Standard Prophylaxis Treatment Of Children With Severe Hemophilia A

Next Previous
Trial Profile

Non-interventional Study To Evaluate Efficacy And Safety Of Refacto Af In The Standard Prophylaxis Treatment Of Children With Severe Hemophilia A

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Moroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 06 Apr 2018 Planned End Date changed from 1 Jul 2020 to 1 Nov 2020.
    • 06 Apr 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Nov 2020.
    • 06 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top